Aspire BioPharma, Inc. (ASBP) - Total Assets
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) holds total assets worth $7.12 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aspire BioPharma, Inc. - Total Assets Trend (2021–2025)
This chart illustrates how Aspire BioPharma, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see ASBP company net worth for the company's overall valuation and market capitalisation.
Aspire BioPharma, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Aspire BioPharma, Inc.'s total assets of $7.12 Million consist of 100.0% current assets and 0.0% non-current assets. Review debt load of Aspire BioPharma, Inc. to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $253.16K | 19.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Aspire BioPharma, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Aspire BioPharma, Inc. share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aspire BioPharma, Inc.'s current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 76.5% of total assets in 2025, up from 0.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 19.3% of total assets.
Aspire BioPharma, Inc. Competitors by Total Assets
Key competitors of Aspire BioPharma, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Aspire BioPharma, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.26 | 0.22 | 1.00 |
| Quick Ratio | 2.14 | 0.22 | 1.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.96 Million | $-6.90 Million | $-475.00 |
Aspire BioPharma, Inc. - Advanced Valuation Insights
This section examines the relationship between Aspire BioPharma, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.61 |
| Latest Market Cap to Assets Ratio | 7.69 |
| Asset Growth Rate (YoY) | 786.7% |
| Total Assets | $1.31 Million |
| Market Capitalization | $10.09 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Aspire BioPharma, Inc.'s assets at a significant premium (7.69x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Aspire BioPharma, Inc.'s assets grew by 786.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aspire BioPharma, Inc. (2021–2025)
The table below shows the annual total assets of Aspire BioPharma, Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.31 Million | +786.66% |
| 2024-12-31 | $147.99K | -99.26% |
| 2023-12-31 | $19.98 Million | -93.34% |
| 2022-12-31 | $300.18 Million | +102273.98% |
| 2021-12-31 | $293.22K | -- |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more